Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review

We report an 11-month-old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off-label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of systemic steroids. Although limited by the small sample size and lack of high-quality data, omalizumab presents as a well-tolerated and potentially effective steroid-sparing agent for pediatric cutaneous mastocytosis.